Global Soft Tissue Allografts Market, By Type (Cartilage Allograft, Tendon Allograft, Meniscus Allograft, Dental Allografts, Others), Application (Orthopedic, Dentistry, Wound Care, Others), End-Users (Hospitals, Aesthetics Centers, Orthopedic Clinics, Dental Clinics, Others) – Industry Trends and Forecast to 2030.
Soft Tissue Allografts Market Analysis and Size
The increasing number of procedures is driving the global soft tissue allografts market. The anterior cruciate ligament (ACL) reconstruction is becoming more common among athletes and is expected to drive market growth for soft tissue allografts. The market is further aided by the need for healthy teeth to stimulate demand. The population's poor lifestyle due to technology addiction will provide impetus to market growth.
Data Bridge Market Research analyses that the soft tissue allografts market which was USD 4.47 billion in 2022, is expected to reach USD 7.53 billion by 2030, at a CAGR of 6.75% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Soft Tissue Allografts Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015 - 2020)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Type (Cartilage Allograft, Tendon Allograft, Meniscus Allograft, Dental Allografts, Others), Application (Orthopedic, Dentistry, Wound Care, Others), End-Users (Hospitals, Aesthetics Centers, Orthopedic Clinics, Dental Clinics, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
CONMED Corporation (U.S.), XTANT MEDICAL (U.S.), ALONSOURCE GROUP (U.S.), BD (U.S.), Arthrex, Inc (U.S.), Bone Bank Allografts (U.S.), Integra LifeSciences (U.S.), Stryker (U.S.), RTI Surgical (U.S.), AlloSource (U.S.), MIMED (U.S.), Institut Straumann AG (Switzerland), Organogenesis Inc (U.S.)
Soft tissue allografts are used in knee surgery to replace deficient ligaments, torn menisci, spinal surgery, and osteochondral defects. The three-stage safety screening process for sterile tissue allografts includes donor screening, laboratory testing, and tissue preparation. Soft tissue allografts, composed of bone, tendons, cartilage, skin, heart valves, and veins, are used in various surgeries. Soft tissue allograft transplantation has been a successful procedure for over 150 years, with approximately one million allografts transplanted in the United States annually.
Soft Tissue Allografts Market Dynamics
- Growing cases of orthopedics and dentistry related to aging
Globally, the prevalence of orthopaedic disorders is increasing, leading to disability and negatively impacting people's physical and mental well-being. Osteoarthritis, one of the most common types of joint disease affecting people over 65 in both developed and developing countries, has a positive impact on the market. Osteoarthritis is characterized by a gradual loss of cartilage in joints, causing the bones to rub against one another, resulting in stiffness, pain, and impaired movement.
- Rise in geriatric population
According to the World Ageing 2019 report, approximately 703 million people worldwide were 65 or older in 2019. It is predicted that there will be 1.5 billion senior citizens by 2050. The proportion of people aged 65 and up increased from 6% in 1990 to 9% in 2019. The percentage is expected to rise by 16% by 2050. By 2050, one in every six people will be over the age of 65, up from one in every eleven in 2019. This indicates that the demand for anterior cruciate ligament surgeries is increasing, boosting soft tissue allografts' growth.
- Advancements in soft tissue replacement
A growing number of clinical trials are being conducted to investigate the efficacy of soft allografts as well as comparisons between xenografts and allografts. Increased research stimulates market growth. According to clinical trials.gov, 46 studies on soft tissue allografts had been completed as of March 15, 2020. For instance, Cairo University, in collaboration with Ahmed Mohamed Ibrahim Elkady, began a trial in 2020 to evaluate the non-incised papilla surgical approach with allograft plus platelet-rich fibrin in the treatment of intraosseous defects in stage III periodontitis patients. Such novel surgical procedures and research with allografts are propelling the market forward.
- High cost of treatment
Although the treatments are promising for treating a variety of soft tissue disorders, their high cost is one of the major barriers to their widespread use among patients. According to Michael R. Karns, MD, in his 2019 article "Patient- and Procedure-Specific Variables Driving Total Direct Costs of Outpatient Anterior Cruciate Ligament Reconstruction(ACLR)," the use of an allograft or hybrid graft, longer operating room time, and concurrent meniscus repair were predictors of an increased direct cost. The study concluded that allografts and hybrid grafts had a higher total direct cost. ACLR has been reported to repair approximately 25% of meniscal tears.
This soft tissue allografts market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the soft tissue allografts market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
- In 2022 – AbbVie (NYSE: ABBV) today announced a slew of new data from studies of risankizumab (SKYRIZI) in Crohn's disease and upadacitinib (RINVOQ) in ulcerative colitis and Crohn's disease that will be presented as live presentations and e-Posters at the United European Gastroenterology (UEG) Week 2022, October 8 AbbVie will present 17 abstracts covering a wide range of inflammatory bowel disease studies (IBD).
- In 2022 – AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CMHP) has adopted a positive opinion recommending approval of risankizumab (SKYRIZI, 600 mg IV induction and 360 mg SC maintenance therapy) for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response, lost response.
Global Soft Tissue Allografts Market Scope
The soft tissue allografts market is segmented on the basis of type, application and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Cartilage Allografts
- Hyaline Cartilage
- Elastic Cartilage
- Fibro Cartilage
- Tendon Allografts
- Achilles Tendon
- Patellar Tendon
- Meniscus Allografts
- Dental Allografts
- Free Gingival Graft
- Connective Tissue Graft
- Pedicle Graft
- Collagen Allografts
- Amniotic Allografts
- Sports Medicine
- Spine Surgeries
- General Orthopedic
- Dental Sensitivity
- Wound Care
- Orthopedic Clinics
- Dental Clinics
- Aesthetic Centers
Soft Tissue Allografts Market Regional Analysis/Insights
The soft tissue allografts market is analyzed and market size insights and trends are provided by country, type, application and end-users as referenced above.
The countries covered in the soft tissue allografts market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the soft tissue allografts market due to advancement in the dental implants, rising healthcare expenditure and increasing development in soft tissue allografts.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the growing incidence of cancer such as bladder, esophagus, liver, pancreas, and others, high presence of major manufacturers across the U.S. Furthermore, technological advancements and rising foreign investment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The soft tissue allografts market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for soft tissue allografts market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the soft tissue allografts market. The data is available for historic period 2011-2021.
Competitive Landscape and Soft Tissue Allografts Market Share Analysis
The soft tissue allografts market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to soft tissue allografts market.
Some of the major players operating in the soft tissue allografts market are:
- CONMED Corporation (U.S.)
- XTANT MEDICAL (U.S.)
- ALONSOURCE GROUP (U.S.)
- BD (U.S.)
- Arthrex, Inc (U.S.)
- Bone Bank Allografts (U.S.)
- Integra LifeSciences (U.S.)
- Stryker (U.S.)
- RTI Surgical (U.S.)
- AlloSource (U.S.)
- MIMED (U.S.)
- Institut Straumann AG (Switzerland)
- Organogenesis Inc (U.S.)